JP MORGAN/CALL/VERTEX PHARMACEUTICALS/440/0.1/17.01.25 | Market Closed - Börse Stuttgart 01:05:49 21/06/2024 pm IST | ||
| 6.47 EUR | +3.85% |
|
| Current month | +31.50% | ||
| 1 month | +26.12% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 21/24/21 | 6.47 | +3.85% |
| 20/24/20 | 6.23 | +2.30% |
| 19/24/19 | 6.09 | -8.01% |
| 18/24/18 | 6.62 | -7.28% |
| 17/24/17 | 7.14 | +2.15% |
Delayed Quote Börse Stuttgart
Last update June 21, 2024 at 01:05 pm IST
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JL795A |
| ISIN | DE000JL795A2 |
| Date issued | 19/07/2023 |
| Strike | 440 $ |
| Maturity | 17/01/2025 (210 Days) |
| Parity | 10 : 1 |
| Emission price | 2.94 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.51 € |
|---|---|
| Lowest since issue | 2.19 € |
| Spread | 0.3 € |
| Spread % | 4.62% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
468.7
USD
Average target price
463.4
USD
Spread / Average Target
-1.13%
- Stock Market
- Warrants
- Warrant
